28.12.2020 20:10:29
|
Drugmakers To Cut Prices By Half To Get On China's Medical Insurance List
(RTTNews) - Drugmakers have agreed to cut prices by around 50% for 119 medicines in order to have them included in China's state medical insurance scheme from March.
China's National Health Security Agency announced that some 119 medications have been included into the latest national essential drug list for reimbursement after considerable cuts in their prices.
These drugs were among the 162 drugs that were included in price negotiations between the administration and their producers earlier this year. Following price negotiations their cost dropped by nearly 51 percent on average, according to the administration.
Ninety-six of them are branded drugs with no generic versions available in the domestic market, according to the statement.
The drugs include some key products made by foreign pharmaceutical companies, such as Novartis' inflammation drug Cosentyx, and Teva Pharmaceutical's Austedo treatment for Huntington's disease.
Some antiviral drugs, including Arbidol and Ribavirin, which can be used for treating COVID-19, are among the new drugs that were added to the list.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novartis AG (Spons. ADRS)mehr Nachrichten
11.02.25 |
Novartis investiert Milliarden in US-Unternehmen Anthos Therapeutics - Aktie höher (Dow Jones) | |
31.01.25 |
Novartis-Aktie zieht an: Novartis erhöht Dividende nach beeindruckendem Umsatz- und Gewinnplus (finanzen.at) | |
30.01.25 |
Ausblick: Novartis öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) | |
21.01.25 |
Novartis-CEO: Gesundheitspolitik der US-Regierung könnte sich unter Trump verbessern - Novartis-Titel höher (Dow Jones) | |
16.01.25 |
Erste Schätzungen: Novartis legt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
21.11.24 |
Neue Markteinführungen beflügeln: Novartis sieht stärkere Umsatzzuwächse bis 2028 - Novartis-Aktie dennoch tiefer (finanzen.at) | |
29.10.24 |
Novartis nach gutem dritten Quartal zuversichtlicher - Aktie dennoch verlustreich (Dow Jones) | |
28.10.24 |
Ausblick: Novartis stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) |
Analysen zu Novartis AG (Spons. ADRS)mehr Analysen
Aktien in diesem Artikel
Novartis AG (Spons. ADRS) | 101,50 | -0,49% |
|
Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 15,50 | -0,96% |
|